Lastly, accurate and rapid evaluation of novel immunomodulatory therapy methods to curb BCM destruction, such as using pancreatic glutamic acid decarboxylase (GAD) autoantigens administration for an improved T-cell immunity reaction [30,31,32], or anti-CD3 monoclonal antibodies treatment to stimulate regulatory T-cells activity [33], is challenging without a direct readout of BCM. Here, GAD1 is linked to blue cone monochromacy.